Ischemic Stroke – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23002IDB-L5

Select Item

Empower your strategies with our Ischemic Stroke – Drugs In Development, 2024 report and make more profitable business decisions.

Ischemic stroke occurs when there is a disruption of blood flow to a part of the brain, leading to a lack of oxygen and nutrients. This can happen when a blood vessel that supplies blood to the brain becomes blocked or narrowed, often due to the formation of a blood clot or plaque buildup within the vessel. The blockage can occur within the blood vessels of the brain itself (cerebral arteries) or can be due to emboli, which are clots or debris that travel from other parts of the body to the brain. Ischemic strokes are the most common type of stroke, accounting for the majority of stroke cases.

There are two main subtypes of ischemic stroke: 1.Thrombotic stroke occurs when a blood clot (thrombus) forms within one of the arteries that supply blood to the brain. The clot may develop in an already narrowed or atherosclerotic artery. 2. Embolic stroke happens when a blood clot or other material (an embolus) forms in another part of the body, such as the heart or a large artery, and then travels to the brain through the bloodstream, causing a blockage in a smaller blood vessel in the brain.

The Ischemic Stroke drugs in development market research report provide comprehensive information on the therapeutics under development for Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ischemic Stroke and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Ischemic Stroke
Key Targets
· Plasminogen; Free Radical; Tissue Type Plasminogen Activator; Coagulation Factor XI; Disks Large Homolog 4; P2Y Purinoceptor 12; Von Willebrand Factor; Glutamate Receptor Ionotropic NMDA 2B; Brain Derived Neurotrophic Factor; and Complement C1s Subcomponent
Key Mechanisms of Action
· Plasminogen Activator; Free Radical Scavenger; Coagulation Factor XI Inhibitor; Disks Large Homolog 4 Inhibitor; Tissue Type Plasminogen Activator Replacement; Von Willebrand Factor Inhibitor; P2Y Purinoceptor 12 Antagonist; Complement C1s Subcomponent Inhibitor; Brain Derived Neurotrophic Factor Activator; and Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist
Key Routes of Administration
· Intravenous; Oral; Parenteral; Subcutaneous; Intravenous Drip; Intravenous Bolus; Intracerebral; Sublingual; Intramuscular; and Intraarticular
Key Molecule Types
· Small Molecule; Cell Therapy; Synthetic Peptide; Monoclonal Antibody; Recombinant Protein; Recombinant Enzyme; Recombinant Peptide; Fusion Protein; Biologic; and Peptide
Major Companies
· Simcere Pharmaceutical Group Ltd; Suzhou Pharmavan Cancer Research Center Co Ltd; Saillant Therapeutics BV; Chengdu Shibeikang Biomedical Technology Co Ltd; Allife Medical Science and Technology Co Ltd; Neurodawn Pharmaceutical Co Ltd; NoNO Inc; Les Laboratoires Servier SAS; AntiRadical Therapeutics LLC; and Bayer AG

Scope

  • Therapeutics in Development: Covering 212 molecules, with 189 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Ischemic Stroke therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Ischemic Stroke pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Ischemic Stroke treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

AbbVie Inc
Acticor Biotech SAS
Advanced BioMatrix Inc
AegisCN LLC
Akome Biotech Ltd
AlaMab Therapeutics Inc
Allife Medical Science and Technology Co Ltd
Anthos Therapeutics Inc
AntiRadical Therapeutics LLC
Apellis Pharmaceuticals Inc
Aposcience AG
APT Therapeutics Inc
AptaTargets SL
Argenica Therapeutics Ltd
ArunA Bio Inc
Astrocyte Pharmaceuticals Inc
Athersys Inc
Autonomous University of Barcelona
Avilex Pharma ApS
Basking Biosciences Inc
Bayer AG
Beijing Darwin Cell Biotechnology Co Ltd
Beijing Yinfeng Dingcheng Bioengineering Co Ltd
Bilix Co Ltd
Biogen Inc
Biosios (Beijing) Biotechnology Co Ltd
Bioxytran Inc
Bolden Therapeutics Inc
Brain-Gen LLC
Bristol-Myers Squibb Co
CarboMimetics
CardioCell LLC
Celdara Medical LLC
Center for Drug Research and Development
Cenyx Biotech Inc
CervoMed Inc
CHA Biotech Co Ltd
Changzhou Qianhong Bio-Pharma Co Ltd
Charite University Hospital of Berlin
Chengdu Shibeikang Biomedical Technology Co Ltd
China Pharmaceutical University
China Resources Emde Biological Pharmaceutical Co Ltd
Clinuvel Pharmaceuticals Ltd
Cogentis Therapeutics Inc
CohBar Inc
Constant Therapeutics LLC
CrestecBio Co Ltd
Crioestaminal Saude e Tecnologia SA
CSPC Pharmaceutical Group Ltd
DiaMedica Therapeutics Inc
Diapin Therapeutics LLC
Edvince AB
Egret Therapeutics Inc
Eight Plus One Pharmaceutical Co Ltd
Elicio Therapeutics Inc
Epigen Biosciences Inc
Epygen Biotech Pvt Ltd
European Institute of Oncology
First Condor Group
Florida Atlantic University
Freeox Biotech SL
Genentech USA Inc
Genervon Biopharmaceuticals LLC
Glucox Biotech AB
GNT Pharma Co Ltd
Guangzhou Cellprotek Pharmaceutical Co Ltd
Guangzhou Magpie Pharmaceutical Co Ltd
Guangzhou Recomgen Biotech Co Ltd
Guangzhou-Sheng Jian Chi Pharmaceutical Co Ltd
Guidon Pharmaceutics Inc
Gwoxi Stem Cell Applied Technology Co Ltd
Haimen Shengyuan Stem Cell Technology Co Ltd
Heart Research Institute Ltd
Hefei Medical & Pharmaceutical Co Ltd
Hibernaid Inc
Hillhurst Biopharmaceuticals Inc
Hopstem Biotechnology LLC
Hoth Therapeutics Inc
Immunwork Inc
Infensa Bioscience Pty Ltd
Institut National de la Recherche Scientifique
International Stem Cell Corp
iRegene Therapeutics Co Ltd
Jeil Pharmaceutical Co Ltd
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Ouwei Pharmaceutical Co Ltd
Jiangsu Wangao Pharmaceutical Co Ltd
Kai Nuo Bio Sci Co Ltd
Kaohsiung Medical University
Kunming Pharmaceutical Group Co Ltd
Laminar Pharmaceuticals SA
Les Laboratoires Servier SAS
Life Sciences Institute
Lumosa Therapeutics Co Ltd
Lys Therapeutics SAS
M et P Pharma AG
Marizyme Inc
Meridigen Biotech Co Ltd
Mitoconix Bio Ltd
NC Medical Research Inc
NeuExcell Therapeutics Inc
Neurevo GmbH
Neurexis Therapeutics Inc
Neurodawn Pharmaceutical Co Ltd
NeuroNascent Inc
NeurOp Inc
Neurophyxia BV
NeuroTrauma Sciences LLC
NoNO Inc
Novo Nordisk AS
NuvOx Pharma LLC
Omniox Inc
Osaka University
OTR3 SAS
Oxitope Pharma BV
Pharmazz Inc
Pharming Group NV
Phoenix Biotechnology Inc
PhytoHealth Corp
Primary Peptides Inc
Prolong Pharmaceuticals LLC
Protheragen Inc
Q32 Bio Inc
Qingdao Primedicine Pharmaceutical Technology Co Ltd
Ramon y Cajal Institute of Health Research
Reliance Life Sciences Pvt Ltd
Remedium Bio Inc
ReNeuron Group Plc
Revalesio Corp
Rubicon Biotechnology Inc
Saillant Therapeutics BV
Salk Institute for Biological Studies
SanBio Co Ltd
Saneron CCEL Therapeutics Inc
Sanofi
Savara Inc
Shanghai Aisar Biotechnology Co Ltd
Shanghai Braegen Pharmaceutical Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Fosun Pharmaceuticals Industrial Development Co Ltd
Shanghai Hutchison Pharmaceuticals Ltd
Shanghai Pharmaceutical Group Co Ltd
Shenzhen Wingor Biotechnology Co Ltd
Shijiazhuang Yiling Pharmaceutical Co Ltd
Shimao Tianjie Pharmaceutical (Jiangsu) Co Ltd
Shin Poong Pharm Co Ltd
Shionogi & Co Ltd
Silver Creek Pharmaceuticals Inc
Simcere Pharmaceutical Group Ltd
SL Bigen Co Ltd
SNJ Pharma Inc
Starpax Biopharma Inc
StemCyte Inc
Stream Biomedical Inc
Surrozen Inc
Suzhou Auzone Biological Technology Co Ltd
Suzhou Pharmavan Cancer Research Center Co Ltd
Synaptogenix Inc
TagCyx Biotechnologies
TargED Biopharmaceuticals BV
Tasly Pharmaceutical Group Co Ltd
Theertha Biopharma Pvt Ltd
TheraSource LLC
Theratome Bio Inc
Thrombolytic Science International LLC
TikoMed AB
TNAX Biopharma Corp
Translational Sciences Inc
TrueBinding Inc
U.S. National Institutes of Health
University Hospital Geneva
University of Connecticut
University of Havana
University of Nebraska
University of North Carolina at Chapel Hill
University of Pittsburgh
University of Tennessee
Vanworld Pharmaceutical (Rugao) Company Ltd
Vect-Horus SAS
Virogenomics BioDevelopment Inc
VST Bio Corp
YouCare Pharmaceutical Group Co Ltd
Zhejiang Ausun Pharmaceutical Co Ltd
Zhengzhou University
Zocere Inc
Zonhon Biopharma Institute Inc
ZZ Biotech LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Ischemic Stroke reports
Pharmaceuticals
New
Bio/Pharmaceutical Outsourcing Report, February 2026
$2,950 | March 2026
Pharmaceuticals
New
Precision and Personalized Medicine - Advanced Therapeutics: Strategic Intelligence
$3,450 | February 2026
Pharmaceuticals
New
Human Immunodeficiency Virus (HIV) Infections (AIDS): Global Clinical Trials Review,…
$3,450 | February 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Ischemic Stroke – Drugs In Development, 2024 in real time.

  • Access a live Ischemic Stroke – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more